Amgen Inc. (AMGN)

175.37
0.54 0.31
NASDAQ : Health Technology
Prev Close 174.83
Open 175.42
Day Low/High 171.79 / 176.68
52 Wk Low/High 152.16 / 201.23
Volume 3.42M
Avg Volume 5.07M
Exchange NASDAQ
Shares Outstanding 668.27M
Market Cap 114.90B
EPS 2.70
P/E Ratio 63.92
Div & Yield 5.28 (2.73%)

Latest News

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

These 2 Widely Held Stocks Look Good Short

These 2 Widely Held Stocks Look Good Short

Our 'bearish bets' show weak technical characteristics and have received recent quant downgrades.

Amgen’s Chart Needs a New Drug, Plus 4 Other Bearish Bets

AMGN, BIG, BSET, YRD and CRUS were all recently downgraded by TheStreet's Quant Ratings service.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BAM, BBBY, LMNR, TCAP Downgrades: AMGN, HQCL, HRZN, MRCC, NMFC, PAR, PKOH, SHLM, SSB, TEDU, UBSI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients

FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children

FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children

BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)

New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events

New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events

Research Presented at American College of Cardiology's 67th Annual Scientific Session Reveals More Than 110,000 Cardiovascular Events a Year Could Occur in High-Risk Patients With Cardiovascular Disease who are Rejected Access

DowDuPont, Sorrento Therapuetics, Lockheed Martin: 'Mad Money' Lightning Round

DowDuPont, Sorrento Therapuetics, Lockheed Martin: 'Mad Money' Lightning Round

Jim Cramer highlights DowDuPont, Sorrento Therapuetics, Lockheed Martin, ZAGG, Worldpay, Pattern Energy, AMC Networks.

The Sky Is Not Falling: Cramer's 'Mad Money' Recap (Tuesday 3/6/18)

The Sky Is Not Falling: Cramer's 'Mad Money' Recap (Tuesday 3/6/18)

Trade wars, tariffs, Gary Cohn's resignation... yes, all shocking. But investors need to buy what's working, says Jim Cramer.

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe

Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe

Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)

First-Ever Application to be Submitted for an MRD Positive Indication

Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

XGEVA Successfully Met Primary Endpoint of Non-Inferiority Versus Zoledronic Acid in Delaying Time to First On-Study Skeletal-Related Event

Amgen Becomes #38 Most Shorted Nasdaq 100 Component, Replacing Charter Communications

Amgen Becomes #38 Most Shorted Nasdaq 100 Component, Replacing Charter Communications

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Amgen and why Chaikin says to be careful of the stock.

TheStreet Quant Rating: C+ (Hold)